Medtech - An attractive market for private equity

Attractive business model coupled with market liquidity are driving up premiums however significant care should be taken on finding the right asset

Read more

Body countouring - The next botox?

Following Allergan's announcement on 13 February of its acquisition of bodycountouring specialist ZELTIQ for $2.7bn...

Read more

The future of UK pharmacies

UK pharmacy valuations have been on the rise driven by significantly more demand than supply for pharmacy acquisitions. The UK…

Read more

RSS RECENT NEWS

  • ADCs’ inflection point February 16, 2019
    The ADC field will soon find out whether the next generation’s combinations of dials and levers can widen the limited therapeutic window of the earlier technology.
  • NodThera: Inhibiting the inflammasome for NASH February 16, 2019
    NodThera is tackling NASH by inhibiting the NLRP3 inflammasome to address both the inflammatory and fibrotic drivers of disease.
  • Embedding digital in Lilly’s portfolio February 16, 2019
    While other chief digital officers have company-wide remits, Lilly’s is focused on developing tools that can turn therapies into better, more comprehensive outcomes.
  • Andera looks early for cancer immunotherapy February 16, 2019
    How Andera diversified its late-stage cancer immunotherapy portfolio via a £10 million A round for Grey Wolf.
  • Earnings on deck February 16, 2019
  • 5AM seizes a new Opportunity February 15, 2019
    5AM Ventures raised $147 million in its first Opportunities fund so the firm can allocate more capital to existing portfolio companies
  • HKEX: where East meets West February 14, 2019
    HKEX CEO Charles Li talks to BioCentury about the health of China’s rising biotech sector, the exchange’s role in connecting East to West and his expectations for 2019.
  • Killing Part D rebates February 9, 2019
    Killing rebates in Medicare Part D is great for biopharma and senior citizens with high drug costs, and bad for PBMs.
  • Genentech takes the wheel February 9, 2019
    First order of business for the new Genentech leadership at Roche will be to up its immunotherapy game if the pharma is to retain its pole position in cancer.
  • Merck KGaA's large-scale partnering February 9, 2019
    Merck KGaA’s deal with GSK for M7824 signals a strategy to partner its high value assets with players who can accelerate development and get them to broad markets quickly.